New York Magazine examines cancer drug pricing

Share this article:
New York Magazine examines cancer drug pricing
New York Magazine examines cancer drug pricing

In a story published online on October 20th, New York magazine took readers through the Memorial Sloan-Kettering/Zaltrap pricing battle with Leonard Saltz, one of the three oncologists who penned the op-ed in the New York Times which started it all and concluded with Sanofi/Regeneron slashing the price of then new breast cancer drug Zaltrap in half due to "market resistance."

The seven-page article online also quoted Hagop Kantarjian, head of the Department of Leukemia at the University of Texas's MD Anderson Cancer Center, who is currently campaigning against Gleevec, a leukemia treatment whose price has tripled since 2001.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.